• Careers
  • Contact Us

Portola Pharmaceuticals

Discovering and developing novel therapeutics.

Menu

Skip to content
  • :About Us
    • :Leadership Team
    • :Board of Directors
    • :Scientific Advisory Board
    • :Translational Advisory Board
    • :Collaborations
    • :Business Development
  • :Product Pipeline
    • :Betrixaban: FXa Inhibitor
    • :PRT4445: FXa Inhibitor Antidote
    • :PRT2070: Dual Syk-JAK Inhibitor
    • :PRT2607: Syk-Specific Inhibitor
    • :Clinical Trials
    • :Publications
  • :Newsroom
  • :Investor Relations
  • slide1-bg
    Innovative Science
    Innovative Science
    Patient Focused
    Portola Pharmaceuticals is focused on the development and commercialization of novel therapeutics to meet patient needs in thrombosis, other hematologic disorders and inflammation. Learn More.

Product Pipeline

Thrombosis Pre-
Clinical		 Phase
1		 Phase
2		 Phase
3
BETRIXABAN
Anticoagulant –
oral, FXa inhibitor
     
PRT4445
rFXa inhibitor antidote
     
Hematologic Cancers
& Inflammation		        
PRT2070
Oral dual Syk & JAK inhibitor
     
PRT2607
Syk–selective inhibitors
     

Clinical Trials

Betrixaban
Phase 3 APEX Study (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban)

APEX Study

PRT4445
Series of Phase 2 proof-of-concept studies in healthy volunteers who have been administered a mexedrone inhibitor

Learn more

News & Events

  • 06/12/13 - Portola Pharmaceuticals to Present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference
  • 05/28/13 - Portola Announces Closing of Initial Public Offering and Over-Allotment Option Exercise
  • 05/22/13 - Portola Announces Pricing of Initial Public Offering
  • 05/08/13 - Portola Announces PRT4445 Produces Rapid, Sustained and Dose-Related Reversal of Anticoagulant Activity of Eliquis® in Phase 2 Study

Archive

© 2016 Portola Pharmaceuticals, Inc. All rights reserved.
  •    Site Map
  •    Terms of Use
  •    Privacy Policy